Abstract Body

Background: Precise genome-editing techniques have been developed recently that allow researchers to delete, insert, and modify DNA in human cells and other animal cells grown in culture. These technologies include zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the clustered regulatory interspaced short palindromic repeat (CRISPR) system. This review will focus mainly upon the most recently described Cas9/CRISPR system as a tool that can be readily employed in individual laboratories. Conclusions: The emerging technology of genome editing is based on the use of engineered nucleases to produce specific DNA cleavages at defined target sites. Repair of these cleavages by host enzymatic machinery, either non-homologous end-joining (NHEJ) or homologous recombinational (HR) repair, results in either loss/insertion of some sequence or substitutions in the broken region. This review will describe site-specific nuclease technologies and discuss their employment for genetic analysis and manipulation for both research and potential therapeutic application. ZFNs and TALENs rely upon sequence-specific DNA-binding domains fused to a nonspecific DNA cleavage module. Although the modular nature of the ZFN and TALEN DNA recognition domains permits design and production of nucleases targeting of virtually any sequence, they can be difficult to produce by individual labs prompting many to use commercial sources. Unlike ZFN or TALEN, the CRISPR/Cas9-mediated genome editing system utilizes a small guide RNA to recognize and direct activity of the endonuclease. This system can be effectively employed by individual labs and the tools for utilizing CRISPRs are readily available. In addition to gene editing in cultured cells where numerous groups have used CRISPRs to create genetic knockouts and gene replacements, they have also been used to create gene modifications in whole animals such as mice, rats, and zebrafish. Very recent advances have demonstrated application of the CRISPR and TALEN mutagenesis approaches in nonhuman primates where one can model disease and develop therapeutic strategies with obvious direct application to HIV infection. Finally, important hurdles that remain before CRISPR-mediated gene correction could be used for therapeutic applications will be discussed